Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Exclusion Criteria

• •1. Prior anti-PDAC therapy (e.g., chemotherapy, radiotherapy, targeted therapy, immunotherapy and therapeutic tumor vaccines) prior to initiation of study treatment.
• •2. Unsuitable for immunotherapy assessed by the investigator.
• •3. Plan to receive a live-attenuated vaccine within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment.
• •4. Have any active autoimmune disease, or have a history of autoimmune disease and have received systemic therapy in the past 2 years.
• •5. Active tuberculosis or a history of active tuberculosis infection within 28 days prior to initiation of study treatment.
• •6. Known or highly suspected history of interstitial pneumonia.
• •7. Allergic to research drug ingredients, or have a history of severe allergic reactions to other vaccines.
• •8. Prior malignancy within 5 years prior to study entry.
• •9. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
• •10. Known splenectomy history.
• •11. Concurrent severe infection within 28 days prior to initiation of study treatment.
• •12. Congenital or acquired immune deficiency.
• •13. Active hepatitis B (HBV-DNA≥1000IU/ml), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of assay).
• •14. Uncontrolled or severe cardiovascular disease.
• •15. Other situations that are not suitable for inclusion in this study judged by investigator.